Device selection: DCB/DES evidence and paclitaxel safety context

in Atherosclerosis and Risk Factors

Applied

Type

Reinforcement

Confidence

90%

Created

Mar 19, 2026

Evidence

1 source

Rationale

The integration of Zhou 2025 provides high-level evidence (network meta-analysis) that reinforces the existing claims regarding DCB and DES efficacy. It adds value by noting that this efficacy is consistent across various lesion locations and severities, which is a more granular finding than the original text. Abbreviations were standardized according to the provided instructions.

Evidence

Zhou Y et al. Network meta-analysis of endovascular treatments for lower extremity arterial disease stratified by lesion location and severity. J Vasc Surg. 2025. PMID: 41338295.
Verified source
PubMedDOI

Content Changes

Paclitaxel-based drug-coated balloons (DCBs)(DCB) and drug-eluting stents (DES) improve patency in femoropopliteal disease compared to uncoated devices. Recent network meta-analysis data reinforces the efficacy of these endovascular treatments across various lesion locations and severities [@zhou2025]. Regulatory review following an initial safety signal (Katsanos 2018) has been ongoing; subsequent large real-world analyses have not confirmed excess mortality.

For detailed device evidence, current regulatory guidance, and shared decision-making requirements, see [[Peripheral Artery Disease|Ch. 10]].
Go to section in textbookDispute / Submit evidenceAll updates